You are looking for

When most people think about chronic conditions, certain disease areas come to mind – diabetes, heart disease, obesity, asthma, allergies…the list goes on.  However, it is unlikely that you think about chronic wounds as being part of that list.  Why is that?  Given that wounds impact 4 million Europeans per year (more than cancer and […]

The impressive spread of mobile connectivity in recent years has attracted attention on the infinite possibilities to transform healthcare services, making them accessible to people regardless of their age, social status or geographical location. Thousands of mobile applications have been developed and hundreds of pilot studies have been launched in an attempt to capture a slice of the pie. With increasing prevalence of cancer and rocketing healthcare costs, could mHealth be a solution for cancer supportive care?  We dig in to find out.

Health will be one of the main topics at this year’s World Economic Forum. It is encouraging to see that the world leaders are recognising that health is a prerequisite for well-being and economic growth. And as a large contributor to health, our industry can play an important role in ensuring that people live longer active lives and contribute to this economic growth.
One look at the rough outline of the different sessions and there are at least seven sessions that are of particular interest.

Despite the overwhelming impact that wounds have on healthcare systems, many people are still unaware of the risks for developing wounds when entering a healthcare setting.  In fact, 27-50 percent of acute hospital beds are likely to be occupied on any day by patients with a wound. Many of these patients will be at high risk of infection, which can result in extended hospital stays and for some, amputation.  Yet, patients can be better protected against such risks by instituting evidenced based guidelines in healthcare settings that include multidisciplinary approaches to wound care treatment.

According to EDMA’s 2012 European In Vitro Diagnostics (IVD) Market Statistics Report, the in vitro diagnostics market in Europe has decreased 2.2% in 2012. These results had been predicted in the previous EDMA report released for 2011, given austerity measures to cut costs in health expenditure. However, a decline in revenue for IVDs might have bad effects in the health of Europeans: there is good reason to believe that governments should invest in IVDs when trying to save money in healthcare.

In the past, percussion of the abdomen, taking temperature, or tasting sugar in urine were considered diagnostic standard of care methodologies. Today, invitro diagnostics (IVD) provide additional objective biomarkers that diagnose cancer, infections, heart attacks and many other health conditions.

In June, the US Supreme Court issued its opinion in the Myriad case (Association for Molecular Pathology v. Myriad Genetics Inc.).  The Supreme Court had been asked a seemingly simple question: “Are human genes patentable?”, and concluded that naturally occurring gene sequences are no longer patentable in the US.  In Europe, isolated gene sequences are still patentable, under certain conditions.  However, the differences between the two legal regimes are not as stark as might initially appear, and the practical effect for the diagnostics industry is complex.

Nowadays everyone seems convinced of the clinical benefits that medical technologies, devices and diagnostics, bring to the table. Many even recognise that our innovations bring about considerable socio-economic benefits. And yet, in the end I hear the same thing over and over again: medical technology drives the rise in healthcare expenditure.
EDMA and Eucomed have always refuted this claim and now we have research by the European Health Technology Institute (EHTI) which basically confirms two of our points of view:

My background in women’s rights has driven me to look into how my current field of work has taken issues which affect women into account. So as an EDMA Communications Intern, I decided to dive into the field of in vitro diagnostics (IVDs) to identify whether the makers of IVDs have played a role in empowering women.  Here’s what my investigation revealed…